Miracle-dz/UniFAR-FTUs huggingface dataset:
The dynamics of embodiment: A field theory of infant perseverative reaching

The overall goal of this target article is to demonstrate a mechanism for an embodied cognition. The particular vehicle is a much-studied, but still widely debated phenomenon seen in 7–12 month-old-infants. In Piaget's classic “A-not-B error,” infants who have successfully uncovered a toy at location “A” continue to reach to that location even after they watch the toy hidden in a nearby location “B. ” Here, we question the traditional explanations of the error as an indicator of infants' concepts of objects or other static mental structures. Instead, we demonstrate that the A-not-B error and its previously puzzling contextual variations can be understood by the coupled dynamics of the ordinary processes of goal-directed actions: looking, planning, reaching, and remembering. We offer a formal dynamic theory and model based on cognitive embodiment that both simulates the known A-not-B effects and offers novel predictions that match new experimental results. The demonstration supports an embodied view by casting the mental events involved in perception, planning, deciding, and remembering in the same analogic dynamic language as that used to describe bodily movement, so that they may be continuously meshed. We maintain that this mesh is a pre-eminently cognitive act of “knowing” not only in infancy but also in everyday activities throughout the life span.
Epstein-Barr Virus Nuclear Antigen 1 Interacts with Nm23-H1 in Lymphoblastoid Cell Lines and Inhibits Its Ability To Suppress Cell Migration

ABSTRACT Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is expressed in the majority of latency programs in EBV-infected cells and is critical for the maintenance of EBV episomes in the infected cells. EBNA1 is also known to be involved in transcriptional activation and regulates expression of the EBV latent genes, including the EBNAs and LMP1. Thus, EBNA1 is a multifunctional protein with critical functions required for the persistence of the viral genome over successive generations, producing new daughter cells from the infected cell. We identify EBNA1 here as an interacting EBNA with the known suppressor of metastasis and cell migration, Nm23-H1. Nm23-H1 inhibits cell migration when expressed in cancer cells. We show that EBNA1 associates with Nm23-H1 in EBV-infected cells in vitro, as well as in lymphoblastoid cell lines (LCLs). Nm23-H1 predominantly localizes to the cytoplasm in BJAB and 293T cells; however, upon expression of EBNA1, Nm23-H1 is translocated to the nucleus in similar compartments to EBNA1, suggesting a potential functional role that is linked to EBNA1. Convincingly, in EBV-transformed LCLs Nm23-H1 is localized predominantly to the nucleus and colocalizes to similar compartment as EBNA1. Further, we tested the effects of EBNA1 on Nm23-H1-mediated suppression of cell migration and showed that EBNA1 rescues the suppression of cell migration mediated by Nm23-H1. These in vitro studies suggest that EBNA1 plays a critical role in regulating the activities of Nm23-H1, including cell migration, through a mechanism which involves direct interaction of this major regulator in EBV-infected cells.
Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis

Several second-generation bisphosphonates (BPs) are approved in osteoporosis treatment. Efficacy and safety depends on potency of farnesyl pyrophosphate synthase (FPPS) inhibition, hydroxyapatite affinity, compliance and adherence. The latter may be influenced by frequency and route of administration. A literature search using “ibandronate”, “postmenopausal osteoporosis”, “fracture”, and “bone mineral density” (BMD) revealed 168 publications. The Phase III BONE study, using low dose 2.5 mg daily oral ibandronate demonstrated 49% relative risk reduction (RRR) in clinical vertebral fracture after 3 years. Non-vertebral fracture (NVF) reduction was demonstrated in a subgroup (pretreatment T-score ≤ −3.0; RRR 69%) and a meta-analysis of high annual doses (150 mg oral monthly or intravenous equivalent of ibandronate; RRR 38%). Hip fracture reduction was not demonstrated. Long-term treatment efficacy has been confirmed over 5 years. Long term safety is comparable to placebo over 3 years apart from flu-like symptoms which are more common with oral monthly and intravenous treatments. No cases of atypical femoral fracture or osteonecrosis of the jaw have been reported in randomized controlled trial studies. Ibandronate inhibits FPPS more than alendronate but less than other BPs which could explain rate of action onset. Ibandronate has a higher affinity for hydroxyapatite compared with risedronate but less than other BPs which could affect skeletal distribution and rate of action offset. High doses (150 mg oral monthly or intravenous equivalent) were superior to low doses (oral 2.5 mg daily) according to 1 year BMD change. Data are limited by patient selection, statistical power, under-dosing, and absence of placebo groups in high dose studies. Ibandronate treatment offers different doses and modalities of administration which could translate into higher adherence rates, an important factor when the two main limitations of BP treatment are initiation and adherence rates. However, lack of consistency in NVF reduction and absence of hip fracture data limits more generalized use of this agent.
Deep Convolutional Neural Networks Outperform Feature-Based But Not Categorical Models in Explaining Object Similarity Judgments

Recent advances in Deep convolutional Neural Networks (DNNs) have enabled unprecedentedly accurate computational models of brain representations, and present an exciting opportunity to model diverse cognitive functions. State-of-the-art DNNs achieve human-level performance on object categorisation, but it is unclear how well they capture human behavior on complex cognitive tasks. Recent reports suggest that DNNs can explain significant variance in one such task, judging object similarity. Here, we extend these findings by replicating them for a rich set of object images, comparing performance across layers within two DNNs of different depths, and examining how the DNNs’ performance compares to that of non-computational “conceptual” models. Human observers performed similarity judgments for a set of 92 images of real-world objects. Representations of the same images were obtained in each of the layers of two DNNs of different depths (8-layer AlexNet and 16-layer VGG-16). To create conceptual models, other human observers generated visual-feature labels (e.g., “eye”) and category labels (e.g., “animal”) for the same image set. Feature labels were divided into parts, colors, textures and contours, while category labels were divided into subordinate, basic, and superordinate categories. We fitted models derived from the features, categories, and from each layer of each DNN to the similarity judgments, using representational similarity analysis to evaluate model performance. In both DNNs, similarity within the last layer explains most of the explainable variance in human similarity judgments. The last layer outperforms almost all feature-based models. Late and mid-level layers outperform some but not all feature-based models. Importantly, categorical models predict similarity judgments significantly better than any DNN layer. Our results provide further evidence for commonalities between DNNs and brain representations. Models derived from visual features other than object parts perform relatively poorly, perhaps because DNNs more comprehensively capture the colors, textures and contours which matter to human object perception. However, categorical models outperform DNNs, suggesting that further work may be needed to bring high-level semantic representations in DNNs closer to those extracted by humans. Modern DNNs explain similarity judgments remarkably well considering they were not trained on this task, and are promising models for many aspects of human cognition.
Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts.

Cultured rat lung fibroblasts were used to explore desensitization of guanylate cyclase to nitrovasodilators. The effect of pretreatment with glyceryl trinitrate (GTN) on the concentration-response curves of GTN and sodium nitroprusside (SNP) for cyclic GMP accumulation in intact cells and activation of guanylate cyclase in broken cell preparations was measured. Pretreatment of cells with 1 microM GTN for 3 h decreased cyclic GMP accumulation induced by GTN but had no effect on SNP-induced cyclic GMP accumulation. Pretreatment of cells with 100 microM GTN decreased the efficacy of GTN and SNP for cyclic GMP elevation by 89% and 40%, respectively. In contrast to results obtained with GTN, SNP slightly desensitized cyclic GMP accumulation induced by GTN and SNP. Pretreatment of cells with 100 nM atrial natriuretic peptide resulted in a 44% decrease in cyclic GMP accumulation induced by subsequent exposure to 10 nM atrial natriuretic peptide but had no effect on cyclic GMP elevation induced by nitrovasodilators. In experiments with crude preparations of soluble guanylate cyclase from cells pretreated with 1 mM GTN, activation of the enzyme by GTN and SNP was inhibited almost completely. Tolerance to GTN in intact cells could not be reversed by subsequent incubation with thiols such as cysteine, N-acetylcysteine or glutathione. However, overnight incubation of GTN-tolerant cells in media without added thiols resulted in complete recovery of responsiveness to GTN. Recovery of GTN-induced cyclic GMP accumulation was inhibited in a concentration-dependent manner by cycloheximide, suggesting that reversal of organic nitrate tolerance requires de novo synthesis of gyanylate cyclase. (ABSTRACT TRUNCATED AT 250 WORDS)
A proposed method for the relative quantification of levels of circulating microRNAs in the plasma of gastric cancer patients

Gastric cancer (GC) is the fifth most common type of malignancy and the third leading cause of cancer-associated mortality worldwide. It is necessary to identify novel methods aimed at improving the early diagnosis and treatment of GC. MicroRNA expression profiles in the plasma of patients with GC have demonstrated a potential use in the opportune diagnosis of this neoplasm. However, there are currently no standardized targets for use in the normalization of microRNA Cq values for different neoplasms. The present study tested two normalization approaches while analyzing plasma derived from patients with GC and non-atrophic gastritis. The first method utilized a panel of small nucleolar RNAs (snoRNAs) and a small nuclear RNA (snRNA) provided by a commercial array. The second normalization approach involved the use of hsa-miR-18a-5p and hsa-miR-29a-3p, which were identified by a stability analysis of the samples being tested. The results revealed that the snoRNAs and snRNA were not expressed in all samples tested. Only the stable microRNAs allowed a narrow distribution of the data and enabled the identification of specific downregulation of hsa-miR-200c-3p and hsa-miR-26b-5p in patients with GC. hsa-miR-200c-3p and hsa-miR-26b-5p have been previously linked to cancer, and a Kyoto Encyclopedia of Genes and Genomes analysis demonstrated that these microRNAs were associated with cell adhesion, cell cycle and cancer pathways.
Precise pose graph localization with sparse point and lane features

We introduce a novel pose graph-based localization technique for autonomous driving that incorporates both sparse point features as well as lane markings on the road. Unlike many commonly used filter methods, our graph-based localization takes a much larger history of the trajectory into account. In addition, we utilize a multiple-hypothesis approach for data association for increased robustness against the presence of outliers. By incorporating both sparse point features and lane markings, we are able to take advantage of both kinds of features widely available in urban environments as well as highways. Furthermore, by using high level features, we avoid having to store and match against large amounts of data such as dense 3D point clouds. Finally, we evaluate our approach on real driving sequences on city roads.
A new brain‐derived neurotrophic factor transcript and decrease inbrain‐derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex

Brain‐derived neurotrophic factor (BDNF) supports hippocampal, cortical and basal forebrain cholinergic neurons, which lose function in Alzheimer's disease. In Alzheimer's tissues such as hippocampus and parietal cortex, brain‐ derived neurotrophic factor mRNA is decreased three‐ to four‐fold compared with controls. However, the molecular mechanism of the down‐regulation of BDNF in Alzheimer's disease is unknown. The human brain‐derived neurotrophic factor gene has multiple promoters governing six non‐coding upstream exons that are spliced to one downstream coding exon, leading to six different transcripts. Here we report an alternate human splice variant within exon 4I for a total of seven transcripts. Previous brain‐derived neurotrophic factor mRNA measurements in Alzheimer's disease tissue were done using the downstream coding exon present in all transcripts. Using RT‐PCR primers specific for each upstream exon, we observe a significant decrease in three human brain‐derived neurotrophic factor mRNA transcripts in Alzheimer's disease samples compared with controls. Transcripts 1 and 3 each exhibit a two‐fold decrease, and transcript 2 shows a five‐fold decrease. There are no significant differences between control and Alzheimer's disease samples for the other transcripts, including the new splice variant. In rat, both transcripts 1 and 3 are regulated through the transcription factor cAMP response element binding protein, whose phosphorylation is decreased in the Alzheimer's disease brain. This could lead to specific down‐regulation of the brain‐derivedneurotrophic factor transcripts shown here.
Breast Cancer Association with Cytomegalo Virus—A Tertiary Center Case-Control Study

ABSTRACT Purpose: Cytomegalo virus is a ubiquitous virus often associated with congenital infections. Some studied have claimed an association between infection with this virus and development of breast cancer. The aim of this prospective research was to study the difference in Cytomegalo virus sero-positivity among patients with breast cancer and benign breast diseases, and thereby to prove any association. Materials and Methods: This was a hospital based Case-Control study conducted at the General Surgery wards of our hospital, a tertiary level public sector health care institution. This study was done on 130 patients with breast swellings who underwent surgical excision of their lumps over a 1-year period. Patients with histologically proven malignancies were selected as cases while proven benign cases were deemed to be the controls. IgG and IgM antibodies to Cytomegalo virus were checked in the patients from both groups. Results: All of the studied patients turned out to be positive for Immunoglobulin G against Cytomegalo virus while all the patients were found to be negative for Immunoglobulin M. There was no difference in the antibody titers among the benign and malignant cases in the study. Logistic regression calculation was also carried out including the study parameters and other known risk factors. Conclusions: We conclude that there is no association between Cytomegalo virus sero-positivity and breast cancer. Another conclusion is that the studied adult population has been exposed to Cytomegalo virus in some point of their lives. Further studies of a larger magnitude are essential to confirm our results.
Effects of acetylcholinesterase inhibition on quality of recovery from isoflurane-induced anesthesia in horses.

OBJECTIVE To compare effects of 2 acetylcholinesterase inhibitors on recovery quality of horses anesthetized with isoflurane. ANIMALS 6 horses in phase 1, 7 horses in phase 2A, and 14 horses in phase 2B. PROCEDURES The study comprised 3 phases (2 randomized, blinded crossover phases in horses undergoing orthopedic procedures and 1 prospective dose-determining phase). In phase 1, horses were anesthetized with isoflurane and received neostigmine or saline (0.9% NaCl) solution prior to anesthetic recovery. Phase 2A was a physostigmine dose-determining phase. In phase 2B, horses were anesthetized with isoflurane and received neostigmine or physostigmine prior to recovery. Objective recovery events were recorded and subjective visual analogue scale scores of recovery quality were assigned from video recordings. RESULTS Recovery measures in phase 1 were not different between horses receiving neostigmine or saline solution. In phase 2A, 0.04 mg of physostigmine/kg was the highest cumulative dose that did not cause clinically relevant adverse behavioral or gastrointestinal effects. Horses receiving physostigmine had higher mean ± SD visual analogue scale recovery scores (70.8 ± 13.3 mm) than did horses receiving neostigmine (62.4 ± 12.8 mm) in phase 2B, with fewer attempts until sternal and standing recovery. Incidence of colic behavior did not differ among groups. CONCLUSIONS AND CLINICAL RELEVANCE Inhibition with physostigmine improved anesthetic recovery quality in horses anesthetized with isoflurane, compared with recovery quality for horses receiving neostigmine. Inhibition of central muscarinic receptors by inhalation anesthetics may underlie emergence delirium in horses recovering from anesthesia.
Precise Positioning of Marketing and Behavior Intentions of Location-Based Mobile Commerce in the Internet of Things

In the complex environment of the IoT (Internet of Things), the amount of information available is enormous and the number of users also increases at a blistering pace. With a huge number of users, e-commerce marketing strategies in the IoT become extremely important and must be altered accordingly in response to changes in the environment and industry. Hence, the application of IoT technology to mobile commerce allows users to receive integrated information according to time, location, and context using location-based service, and provides them with a more effective shopping experience. The validation results show that external variables indirectly influence behavioral intention through perceived usefulness. The investigation of behavioral intention is used to understand users’ acceptance and using willingness of the store app, which can help narrow the gap between stores and consumers, and help improve operations.
Poly(3,4‐ethylenedioxythiophene) and Its Derivatives: Past, Present, and Future

An overview of one of the most successful conducting polymers, poly(3,4-ethylenedioxythiophene) (PEDT) and its derivatives, is presented, detailing its early development, the synthesis of numerous hybrid and derivative materials, along with a description of the broad array of properties accessible and a description of a set of the more prominent applications in which they can be utilized. Synthetic flexibility and facility is the key to the many new 3,4-ethylenedioxythiophene- (EDT-) based monomers, oligomers, and (co) polymers. These (co) polymers provide highly conducting and especially stable doped states, a range of optical properties with electronic bandgaps varying across the entire visible spectrum, and enhanced redox properties, making them useful for numerous electrochemical devices. Present and future applications for PEDT that are discussed include static charge dissipation films and electrode materials in solid electrolyte capacitors.
Transconjunctival approach to peribulbar block

As increasing numbers of anesthetists perform eye block anesthesia, thorough understandings of peribulbar injection techniques are important for safe practice. There is uncertainty in the literature regarding the optimum needle length, entry point, volume of injectate, and use of single vs double-injection techniques. A modified technique of peribulbar block anesthesia is presented, which offers increased safety, simplicity, low cost, and little change to instrumentation.
Achieving High Efficiency and Improved Stability in ITO‐Free Transparent Organic Light‐Emitting Diodes with Conductive Polymer Electrodes

Efficient transparent organic light‐emitting diodes (OLEDs) with improved stability based on conductive, transparent poly(3,4‐ethylenedioxythiophene): poly(styrenesulfonate) (PEDOT:PSS) electrodes are reported. Based on optical simulations, the device structures are carefully optimized by tuning the thickness of doped transport layers and electrodes. As a result, the performance of PEDOT:PSS‐based OLEDs reaches that of indium tin oxide (ITO)‐based reference devices. The efficiency and the long‐term stability of PEDOT:PSS‐based OLEDs are significantly improved. The structure engineering demonstrated in this study greatly enhances the overall performances of ITO‐free transparent OLEDs in terms of efficiency, lifetime, and transmittance. These results indicate that PEDOT:PSS‐based OLEDs have a promising future for practical applications in low‐cost and flexible device manufacturing.
The Australian approach to peri-operative fluid balance

Purpose of review The role of fluid balance as an important contributor to patient morbidity and mortality in the peri-operative period is only now being understood. Numerous studies in disparate populations undergoing different surgeries suggest that. Recent findings There is wide disparity in fluid administration regimen between speciality, country, and clinician. Recent meta-analyses of published studies have shown that restrictive fluid administration strategies may improve patient-centred outcomes when compared to liberal regimens. Current evidence suggests a significant role for fluid accumulation in the development of peri-operative complications. Fluid balance is best achieved using goal-directed techniques. The evidence base is, at present, sub-optimal, with a paucity of level 1 evidence for clinical decision-making. Summary In the absence of level 1evidence it is difficult to make firm recommendations about practice, though observational and single-centre data suggest a significant survival advantage may be conferred by the peri-operative administration of fluids to monitored physiological targets only. The Australian approach to peri-operative fluid management is to create level 1 evidence. To this end, the development of a large multicentre randomized controlled trial of peri-operative fluid administration is underway.